OnDosis
Stefan Kristo's work experience includes several diverse roles in various companies. Stefan began their career in 1997 as a Production Developer at SKF Actuators AB and later worked as a Production Development professional at Knight Industriteknik AB from 1998 to 2000. In 2000, they joined CARAN AB as a Project Manager until 2007. From 2007 to 2021, Stefan worked at Cochlear, starting as a Project Quality Manager and later becoming a Project Manager and Global Project Manager. Currently, they hold the position of Senior Project Manager at OnDosis, where they also serve as the Head of Design and Development since May 2022.
Stefan Kristo's education history includes several notable accomplishments. In 1991, they attended Frölundagymnasiet, where they pursued the Teknisk linje program, focusing on the field of study of Bygg. Following this, they enrolled at the University of Skövde from 1995 to 1997 and obtained a Bachelor of Science degree in Robotics Technology/Technician. Later in 2006, Stefan attended Wenell for a short period, specializing in Project Management. In 2009, they enrolled at AAMI, where they focused on Design Control. Lastly, in 2012, Stefan studied Lean/SixSigma at Cochlear for a brief period, earning a Greenbelt certificate.
OnDosis
1 followers
OnDosis proprietary technology delivers flexible and individualized dosing of oral medicines formulated as micro units. They are focused on providing reassurance in disease management, supporting adherence and providing greater convenience for patients. OnDosis is currently developing products for individualized dosing in diseases with asignificant burden on patients and healthcare such as ADHD, pain management and immunosuppression for organ transplants. Hundreds of thousands of patients with these conditions could be helped by improved dosing, ultimately leading to improving health care outcomes.The flexibility of OnDosis technology provides the potential for application across several disease areas and patient segments where conventional tablets or capsules often does not provide a good fit for the patient or treatment goal.OnDosis was founded in 2017 and is headquartered in Gothenburg, Sweden, based on an idea that was spun-out from AstraZeneca, using technology based on development work initiated there. It was founded by GU Ventures and Martin Olovsson. OnDosis operates a network of strategic partners across all core functions including formulation and device development, IP, Regulatory and Business Development.